Our focus is on neurochemicals acting on the peripheral and central nervous system

We are enthusiastic about neurochemicals acting as agonists or antagonists on G-protein coupled receptors located in the peripheral and central nervous system. Our goal is to address the clinical needs to diagnose and treat the neurological pathologies at the origin of the disease; thus, avoiding a merely systematic treatment and rather stopping or delaying disease progression.

The chemical structure of small molecules is the key for successful drug design and development for both imaging probes and therapeutics. The combined, interdisciplinary knowledge of medicinal chemists, pharmacists and physicians allows drug adjustment and pave the way towards the application of our substances as tools for image-guided therapy.

The bottleneck of the drug development process is the preclinical screening of a compound library, as we still lack substantial methods for a fast and reliable biological assessment. We developed a complex dynamic 3D-cell culture method, which mimics the tissue situation and has the potential to fasten the screening process. Moreover, it conforms with the 3Rs (reduce, replace, refine) rule in animal ethics and will contribute to reduce the number of animals needed in drug testing.

Our main interests lie in

  • Inventive drug and tracer development of neurochemicals
  • Innovative drug screening methods
  • Interdisciplinary approaches close to medical application

EANM 2021 Plenary Lecture - Isotopes Past and Future

Missed the EANM 2021 plenary lecture on the availability of medicinal radioisotopes.

You can still watch it here.

CBmeds microONE promo video

For the SDG-3 presentation at the austrian parlament, our consortium of the FFG funded microONE project (CBmed, Univie, MUW, among others) produced a nice promo-video. Thank you to Thomas Wadsak for the nice production. (German only)

News and announcements


Our group leader, Verena Pichler, was invited to give an educational talk at the ESRR in coimbra, bridging radiopharmaceutical sciences and computational chemistry.


Lukas presented his recent data on micro- and nanoplastic labelling at the European Molecular Imaging Meeting in Porto.


We are delighted to share our next publication in 2024 published in Chemistry - A European Journal.


A substantial portion of patients do not benefit from programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) checkpoint inhibition therapies, necessitating a deeper understanding of predictive biomarkers. Fresh out of press, our new publication on the development of PD-L1 ligands for the application in Positron emission tomography (PET). Congratulations to the first author Karsten Bamminger.


Verena Maisetschläger-Schwingenschlögl presented her results at the ApoKongress in Schladming.


Our group was invited to present our latest results on micro- and nanoplastic at the research club at the Medical University of Vienna. We are proud to be part of the uONE consortium lead by CBmed and funded by the FFG.